Stockreport

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies [Yahoo! Finance]

Amgen Inc.  (AMGN) 
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
PDF ONWARD2 — which evaluated its pipeline candidate, envudeucitinib, for treating patients with moderate-to-severe plaque psoriasis, a chronic autoimmune skin disease. Bo [Read more]